Iosbio Ltd

Iosbio Ltd, based in Haywards Heath, UK, is a small, active company founded 22 years ago. Employing 14 people and holding £2,623,662 in assets, it operates a real address and is managed by seven directors, though there are no reported owners. The company runs an e-commerce site and regularly imports miscellaneous chemical products, with its last import activity recorded three months ago in November 2024. It operates within the human health activities industries.

The company’s website showcases a focus on revolutionizing immunization through oral vaccines, particularly targeting Epstein-Barr Virus (EBV). Iosbio is developing OraProEBV, a vaccine designed to address a significant unmet need linked to multiple sclerosis, mononucleosis, and cancer. The site highlights proprietary technologies like Enhanced Surface Display (ESD) and AI-assisted antigen design, aiming to create thermostable, self-administered vaccines. The company is actively seeking investment to advance OraProEBV into clinical trials.

Financially, Iosbio Ltd presents a mixed picture. While cash reserves increased by a substantial 120% to £2,000,000, net assets declined 18% to £5,600,000. Accumulated amortisation for intangible assets increased by 23%, reflecting ongoing development costs. Creditors rose by 72%, and bank borrowings increased significantly, suggesting the company is leveraging debt to fuel its operations. The company’s small size (meeting two of three criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees) allows for flexibility, but the decrease in equity is something to keep an eye on. With no auditor mentioned, the financial statements are unaudited.

Registered in England/Wales under the registration number 04497290, with a registered address at RH16 1DB, England, Haywards Heath, Hayworthe House, Market Place.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.